We develop and commercialize clinical-stage, rare disease assets that have originated in pharmaceutical or biotechnology companies and which are not being progressed for strategic reasons. With the streamlined efficiency of a small company and with our internal expertise and external resources we are able to rapidly progress the products into late stage development and the planned subsequent commercialization.
With deep clinical experience in rare and specialty diseases from Phase I through to approval and launch, working with third party resources, Mereo is able to offer a comprehensive, seamless and scalable development capability facilitating rapid transfer and start-up of clinical programs from pharmaceutical partners. We work collaboratively with all stakeholders, including regulators, healthcare authorities and pricing & reimbursement decision-makers and healthcare providers to find the optimum pathways to efficiently bring life-changing therapies to patients who may have no other treatment options.
We seek to maximize the value of our specialty product portfolio through commercial partnerships. This includes our products
- BCT-197 (acumapimod)
Acute Exacerbations of COPD
- BGS-649 (leflutrozole)
- OMP305B83 (navicixizumab)
- OMP-313M32 (etigilimab)
Areas of Interest
We continue to seek new product candidates in rare diseases for potential acquisition especially in bone/musculoskeletal, endocrinology and respiratory diseases.
- Bone / musculoskeletal disease
Including but not limited to Achondroplasia, Fibrodysplasia, Ehlers-Danlos, X-linked Hypophosphatemia, Paget’s disease of bone, and Osteopetrosis.
Including but not limited to Cystic Fibrosis, Idiopathic Pulmonary Fibrosis, Pulmonary Arterial Hypertension, Lymphangioleiomyomatosis, Bronchiectasis, and Interstitial Lung Disease.
Including but not limited to Congenital Adrenal Hyperplasia, Acromegaly, Prader-Willi, Hypoparathyroidism, Growth Hormone Deficiency, Cushing’s disease, Goodpasture (lung), and Wilson disease.
We are particularly interested in clinical stage rare disease opportunities that meet the following criteria: